Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
News|Articles|June 7, 2016
SGS to Offer HDX–MS at West Chester Facility
Author(s)Pharmaceutical Technology Editors
The company plans to introduce HDX–MS in quarter three of 2016 at its West Chester, PA facility.
Advertisement
On June 6, 2016, SGS announced that it will be offering hydrogen deuterium exchange mass spectrometry (HDXâMS) capabilities at its West Chester, Pennsylvania facility. This new service, which is currently undergoing installation, will assist in the full characterization of biological molecules, including biosimilars, SGS said in a press statement.
According to SGS, HDXâMS relies on proteins being exposed to deuterium water at extremely low temperatures, whereby hydrogen atoms on the outside of a folded protein molecule exchange with the deuterium atoms in the water at equilibrium. By analyzing the peptides on which atoms have been exchanged, detailed information on the protein folding can be obtained.
The HDXâMS service is expected to be introduced in quarter three of 2016 at the West Chester facility. SGS said it expects the addition of HDXâMS to increase the array of services for higher order protein analysis at the site, including circular dichroism, analytical ultra-centrifugation, size exclusion chromatography with multi-angle laser light scattering, and Fourier transform infrared spectroscopy.
Source: SGS
Advertisement
Related to this article
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Advertisement
Advertisement